Palliative first-line treatment with weekly high-dose 5-fluorouracil (5-FU) and sodium folinic acid (s-FA) (AIO-schedule) as 24h-infusion plus biweekly oxaliplatin (ox) in patients with definitively nonresectable metastatic colorectal cancer (CRC) following secondary (sec) metastatic resection: An interdisciplinary phase II trial

Folinic Acid ◽

Phase Ii ◽

Phase Ii Trial ◽

High Dose ◽

Line Treatment ◽

First Line ◽

Palliative first-line treatment with weekly high-dose 5-fluorouracil and sodium folinic acid (s-FA) (AIO-schedule) as 24h-infusion plus bi-weekly oxaliplatin (ox) in patients with definitively non-resectable metastatic colorectal cancer (CRC) following secondary (s.) metastatic resection: An interdisciplinary phase II-Trial

Zeitschrift für Gastroenterologie ◽

10.1055/s-0028-1089593 ◽

2008 ◽

Vol 46 (09) ◽

Author(s):

H Albrecht ◽

A Wein ◽

C Meier ◽

N Ostermeier ◽

V Brueckl ◽

...

Keyword(s):

Colorectal Cancer ◽

Folinic Acid ◽

Phase Ii ◽

Phase Ii Trial ◽

High Dose ◽

Line Treatment ◽

First Line ◽

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

British Journal of Cancer ◽

10.1038/bjc.2011.594 ◽

2012 ◽

Vol 106 (3) ◽

pp. 453-459 ◽

Cited By ~ 37

Author(s):

J Souglakos ◽

N Ziras ◽

S Kakolyris ◽

I Boukovinas ◽

N Kentepozidis ◽

...

Keyword(s):

Colorectal Cancer ◽

Unresectable Metastatic Colorectal Cancer

Folinic Acid ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

First Line Treatment ◽

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Cited By ~ 1

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Cited By ~ 83

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)

Annals of Oncology ◽

10.1093/annonc/mdy281.154 ◽

2018 ◽

Vol 29 ◽

pp. viii202

Author(s):

A. De Stefano ◽

G. Nasti ◽

A. Febbraro ◽

G. Rosati ◽

F. Giuliani ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial

European Journal of Cancer ◽

10.1016/j.ejca.2015.02.013 ◽

2015 ◽

Vol 51 (8) ◽

pp. 942-949 ◽

Cited By ~ 27

Author(s):

Guillem Argilés ◽

Mark P. Saunders ◽

Fernando Rivera ◽

Alberto Sobrero ◽

Al Benson ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Modified Folfox6 ◽

A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (I) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3540 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3540-3540

Author(s):

P. Garcia-Alfonso ◽

G. Perez-Manga ◽

M. C. Gonzalez ◽

P. Lopez ◽

E. Gonzalez ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3602 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3602-3602 ◽

Cited By ~ 1

Author(s):

Y. Z. Patt ◽

J. Liebmann ◽

D. Diamandidis ◽

S. G. Eckhardt ◽

M. Javle ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽